Novel activators and small-molecule inhibitors of STAT3 in cancer.

Abstract

Excessive activation of signal transducer and activator of transcription 3 (STAT3) signaling is observed in a subset of many cancers, making activated STAT3 a highly promising potential therapeutic target supported by multiple preclinical and clinical studies. However, early-phase clinical trials have produced mixed results with STAT3-targeted cancer therapies, revealing substantial complexity to targeting aberrant STAT3 signaling. This review discusses the diverse mechanisms of oncogenic activation of STAT3, and the small molecule inhibitors of STAT3 in cancer treatment.

• Authors: Lehe Yang, Shichong Lin, Lingyuan Xu, Jiayuh Lin, Chengguang Zhao, Xiaoying Huang
• Journal: Cytokine & growth factor reviews (Cytokine Growth Factor Rev) Vol. 49 Pg. 10-22 (10 2019) ISSN: 1879-0305 [Electronic] England
• PMID: 31677966 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• STAT3 Transcription Factor
• STAT3 protein, human
• Small Molecule Libraries

Topics

• Cell Proliferation (drug effects)
• Clinical Trials as Topic
• Humans
• Neoplasms (drug therapy)
• STAT3 Transcription Factor (antagonists & inhibitors)
• Signal Transduction (drug effects)
• Small Molecule Libraries (chemistry, therapeutic use)